Department of Chemistry, The University of Western Ontario, 1265 Richmond Street, London, ON, Canada N6A 5B7.
Analyst. 2009 Dec;134(12):2400-4. doi: 10.1039/b912083a. Epub 2009 Oct 6.
One of the current pathways to develop inhibitors that target different steps in the life cycle of the human immunodeficiency virus (HIV) is blocking the function of the HIV-related proteins such as HIV-1 integrase (HIV-1 IN), HIV-1 reverse transcriptase (HIV-1 RT) and HIV-1 protease (HIV-1 PR), which are essential proteins that control the ability of HIV to infect cells, produce new copies of the virus, or cause disease. We have demonstrated for the first time the detection of these enzymes at nanomolar levels using ferrocene (Fc)-conjugated peptides on gold microelectrodes. The interaction between the Fc-conjugated peptides and the enzymes was studied by cyclic voltammetry. As the protein concentration increased, the electrochemical behaviour of the surface-bound Fc- bioconjugate changed, indicating that HIV protein was binding to the peptide film and encapsulating the Fc redox center on the surface. The electrochemical responses shifted to higher potentials and decreased in the current intensity, as the concentrations of the HIV-1 enzymes increased. The optimization studies were performed by changing the pH and NaCl concentration. Control experiments involved the exposure of the Fc-conjugated peptides with all the enzymes. This general procedure can be readily applied in the future to the multiplexed detection of several HIV-related proteins, as well as the high-throughput screening of candidate inhibitors for AIDS therapy.
目前开发针对人类免疫缺陷病毒 (HIV) 生命周期不同步骤的抑制剂的途径之一是阻断 HIV 相关蛋白的功能,如 HIV-1 整合酶 (HIV-1 IN)、HIV-1 逆转录酶 (HIV-1 RT) 和 HIV-1 蛋白酶 (HIV-1 PR),这些是控制 HIV 感染细胞、产生新的病毒副本或导致疾病的必需蛋白。我们首次使用金微电极上的二茂铁 (Fc) 缀合肽在纳摩尔水平上检测到这些酶。通过循环伏安法研究了 Fc 缀合肽与酶之间的相互作用。随着蛋白质浓度的增加,表面结合的 Fc-生物缀合物的电化学行为发生变化,表明 HIV 蛋白与肽膜结合并将 Fc 氧化还原中心包裹在表面上。随着 HIV-1 酶浓度的增加,电化学响应向更高的电位移动,电流强度减小。通过改变 pH 和 NaCl 浓度来进行优化研究。对照实验包括用所有酶暴露 Fc 缀合肽。这种一般程序将来可以很容易地应用于多种 HIV 相关蛋白的多重检测,以及 AIDS 治疗候选抑制剂的高通量筛选。